{"nctId":"NCT00078949","briefTitle":"Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma","startDateStruct":{"date":"2003-08-27","type":"ACTUAL"},"conditions":["Lymphoma"],"count":849,"armGroups":[{"label":"Salvage arm I","type":"EXPERIMENTAL","interventionNames":["Drug: cisplatin","Drug: dexamethasone","Drug: gemcitabine hydrochloride"]},{"label":"Salvage arm II","type":"EXPERIMENTAL","interventionNames":["Drug: cisplatin","Drug: cytarabine","Drug: dexamethasone"]},{"label":"Maintenance arm I","type":"EXPERIMENTAL","interventionNames":["Biological: rituximab"]},{"label":"Maintenance arm II","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"rituximab","otherNames":[]},{"name":"cisplatin","otherNames":[]},{"name":"cytarabine","otherNames":[]},{"name":"dexamethasone","otherNames":[]},{"name":"gemcitabine hydrochloride","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed aggressive non-Hodgkin's lymphoma of 1 of the following subtypes:\n\n  * Diffuse large cell lymphoma (includes primary mediastinal B-cell lymphoma and T-cell-rich B-cell lymphoma)\n  * Prior indolent lymphoma (e.g., follicular center cell lymphoma; marginal zone lymphoma, including extranodal mucosa-associated lymphoid tissue \\[MALT\\] lymphoma; and lymphoplasmacytoid lymphoma) with transformation to diffuse large B-cell lymphoma at relapse\n\n    * Must be histologically confirmed\n    * No transformed lymphoma at diagnosis with subsequent indolent histology without transformation at relapse\n  * Peripheral T-cell lymphoma\n  * Anaplastic large cell lymphoma\n  * Small noncleaved Burkitt-like lymphoma\n* T-cell or B-cell lineage confirmed by immunohistochemistry\n* Clinically or radiologically documented disease meeting either of the following criteria:\n\n  * Measurable disease, defined as at least 1 bidimensionally measurable site of disease using clinical exam, CT scan, or MRI\n\n    * Lymph nodes must be \\> 1.5 cm by physical exam or CT scan\n    * Other non-nodal lesions must be ≥ 1.0 cm by physical exam, CT scan, or MRI\n    * Bone lesions are not considered measurable\n  * Evaluable disease, defined as only nonmeasurable disease, including any of the following:\n\n    * Marrow infiltration\n    * Cytology-confirmed ascites or effusions\n    * Bony involvement\n    * Enlarged liver or spleen\n    * Unidimensionally measurable intrathoracic or abdominal masses\n* Previously treated with 1, and only 1, chemotherapy regimen including an anthracycline and excluding cisplatin, cytarabine, and gemcitabine\n* No uncontrolled CNS involvement by lymphoma\n\n  * No CNS disease at time of relapse\n  * CNS disease diagnosed at initial presentation allowed provided a complete response for CNS disease was achieved and maintained\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 16 to 65\n\nPerformance status\n\n* ECOG 0-3\n\nLife expectancy\n\n* At least 12 weeks\n\nHematopoietic\n\n* Absolute granulocyte count ≥ 1,000/mm\\^3\n* Platelet count ≥ 75,000/mm\\^3\n\nHepatic\n\n* Bilirubin ≤ 1.5 times upper limit of normal (ULN)\n* AST or ALT ≤ 2.5 times ULN (5 times ULN if liver involvement with lymphoma)\n* Hepatitis B status known (for patients with a history of hepatitis B or who are at high risk of hepatitis B infection)\n\nRenal\n\n* Creatinine ≤ 1.5 times ULN\n\nCardiovascular\n\n* No significant cardiac dysfunction or cardiovascular disease\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Willing to complete quality of life questionnaires\n* HIV negative\n* No active, uncontrolled bacterial, fungal, or viral infection\n* No other malignancy within the past 5 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix\n* No other concurrent serious illness or medical condition that would preclude study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* See Chemotherapy\n* Prior rituximab allowed\n\nChemotherapy\n\n* See Disease Characteristics\n* At least 4 weeks since prior IV chemotherapy\n* No prior high-dose chemotherapy with stem cell transplantation\n\nEndocrine therapy\n\n* No concurrent corticosteroids except for physiologic replacement\n\nRadiotherapy\n\n* At least 4 weeks since prior radiotherapy and recovered\n\n  * Exceptions may be made for low-dose, non-myelosuppressive radiotherapy\n* No prior radiotherapy to more than 25% of functioning bone marrow\n* Involved-field radiotherapy may be given to areas of bulky disease at relapse (≥ 5 cm) after stem cell transplantation, according to the center's policy\n\nSurgery\n\n* At least 2 weeks since prior major surgery\n\nOther\n\n* No other concurrent anticancer therapy\n* No other concurrent experimental agents","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Response Rate of Patients After 2 Courses of Chemotherapy","description":"The overall response rate by arm is calculated as total number of responders (CR + CRu + PR) / (all patients in the ITT analysis population).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.2","spread":null},{"groupId":"OG001","value":"44.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Transplantation Rate of Patients After 2 Courses of Chemotherapy","description":"Transplantation rate is defined as the number of patients who respond sufficiently to protocol salvage chemotherapy to be planned for transplantation minus those who do not meet the endpoint of successful transplantation, divided by the number of all randomized patients","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":null},{"groupId":"OG001","value":"48.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Event-free Survival of Patients on Maintenance Randomization (Period 2)","description":"Number of patients who develop EFS event during maintenance randomization (period 2)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Toxic Effect","description":"Number of patients affected by adverse events graded according to CTC Version 2.0. See adverse event (others) for details.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":306},"commonTop":["Fatigue","Nausea","Vomiting","Constipation","Neuropathy-sensory"]}}}